Company ·
Dr. Reddy's Laboratories holds a peptide molecule tracked on the Peptide Exchange board.
Dr. Reddy's Laboratories has 1 molecule on the board and 1 news move logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
GLP-1 receptor agonist peptide, generic version of semaglutide
Dr. Reddy's generic semaglutide injection, cleared by Health Canada in April 2026 and launched in May. Batches were recalled in August for an out of specification impurity and a labelling error.
Log
Dr. Reddy's booked 710 million rupees against revenue for expected returns after an August recall of its semaglutide injection in Canada, on top of a June quarter provision for batches that failed specification.
Holds APP